Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Therapies for Hard-to-Treat Psoriasis
Description
The discussion focuses on challenging forms of psoriasis, specifically high-impact sites such as inverse psoriasis, genital psoriasis, nail psoriasis, and generalized pustular psoriasis (GPP). It highlights that patients with these forms often require systemic therapy due to the inadequacy of topical treatments and their higher likelihood of coexisting conditions. For inverse psoriasis, treatment includes topical steroids and biologics, particularly IL-23 and IL-17 inhibitors, along with some newer topical treatments. Genital psoriasis is frequently underdiagnosed, yet impacts intimate relationships significantly, and similar treatment approaches apply. Nail psoriasis, which can severely affect quality of life and is a strong risk factor for psoriatic arthritis, presents unique challenges. Systemic treatments, including biologics and targeted therapies, show promise, especially in trials that demonstrate effectiveness in clearing nail involvement. GPP, a serious and chronic condition, necessitates rapid clinical recognition and is treated with the IL-36 receptor inhibitor spazolimab, the first FDA-approved agent for GPP, which has shown efficacy in managing flares and preventing recurrence. The presentation concludes by emphasizing the need for special considerations in these high-impact psoriasis areas, advocating for systemic therapy and ongoing research into effective treatments.
View moreConclusions
- High impact sites in psoriasis often fail topical treatments and may require systemic therapy.
- Patients with psoriasis in high impact areas are at an increased risk for psoriatic arthritis.
- For inverse psoriasis, systemic biologics, particularly IL-23 and IL-17 inhibitors, are the most effective treatment options.
- Genital psoriasis is frequently underdiagnosed and significantly affects patients' quality of life, necessitating targeted treatment methods.
- Topical treatments such as corticosteroids and vitamin D analogues are common yet limited in efficacy for genital psoriasis.
- Oral apremilast has demonstrated effectiveness for both genital and inverse psoriasis.
- Nail psoriasis has a substantial quality of life impact and is one of the strongest predictors of psoriatic arthritis.
- Intralesional steroids may provide relief in patients with severe nail psoriasis, although systemic therapies are often more effective.
- Defining psoriasis severity through the Nail Psoriasis Severity Index (NAPSI) can guide treatment decisions.
- In generalized pustular psoriasis (GPP), specialized treatment approaches are critical due to associated morbidity and mortality.
- Spesolimab is currently the only FDA-approved treatment for GPP, highlighting the need for more effective therapies in this area.
- Clin Exp Dermatol. 2016 Jul;41(5):486-9.
- Dermatology. 2021;237(1):46-55.
- J Am Acad Dermatol. 2020 Jan;82(1):117-122.
- Dermatol Ther. 2018 May;31(3):e12589.
- Arthritis Rheum. 2009 Feb 15;61(2):233-9.
- J Eur Acad Dermatol Venereol. 2014 Aug:28 Suppl 5:17-26.
- J Am Acad Dermatol. 2022 Oct;87(4):800-806.
- Br J Dermatol. 2023 May 24;188(6):810-812.
- J Eur Acad Dermatol Venereol. 2023 Feb;37(2):348-355.
- Dermatol Ther (Heidelb). 2021 Jun;11(3):833-844.
- J Am Acad Dermatol. 2024 Mar;90(3):485-493.
- Int J Rheum Dis. 2023 Sep;26(9):1788-1798.
- Nat Rev Rheumatol. 2019 Mar;15(3):153-166.
- Dermatol Ther (Heidelb) (2022) 12:911-920.
- Lancet. 2023 Oct 28;402(10412):1541-1551.
- N Engl J Med. 2021 Dec 23;385(26):2431-2440.
- J Psoriasis Psoriatic Arthritis. 2025 Feb 2:24755303251318976.
- Rheumatol Ther. 2023 Dec;10(6):1503-1518.